Analysts Set GSK PLC Sponsored ADR (NYSE:GSK) Target Price at $44.13

GSK PLC Sponsored ADR (NYSE:GSK) has earned a consensus rating of “Reduce” from the ten ratings firms that are currently covering the firm, MarketBeat reports. Four analysts have rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $44.1250.

GSK has been the subject of several analyst reports. Cfra set a $53.00 price target on shares of GSK in a report on Thursday, October 30th. HSBC reiterated a “reduce” rating on shares of GSK in a research report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of GSK in a research note on Friday, January 16th. Weiss Ratings restated a “buy (b)” rating on shares of GSK in a research note on Monday, December 29th. Finally, Morgan Stanley reaffirmed an “underweight” rating on shares of GSK in a report on Wednesday, January 14th.

GSK News Summary

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK agreed to buy RAPT Therapeutics for $2.2B, giving GSK rights to ozureprubart and strengthening its food?allergy and respiratory/immunology portfolio — a strategic, pipeline?building acquisition. GSK to buy RAPT Therapeutics for $2.2 billion
• Positive Sentiment: Forbion (RAPT investor) announced an exit following the deal, signaling third?party valuation support for the $2.2B price and underscoring investor validation of RAPT’s assets. Forbion Announces Second Exit…
• Neutral Sentiment: Multiple industry writeups and an M&A call/slideshow provide deal detail and modeling that help investors assess the pipeline and financial impact but contain no new deal terms. GSK plc (GSK) RAPT Therapeutics, Inc. – M&A Call – Slideshow
• Neutral Sentiment: GSK subsidiary Tesaro signed an exclusive license agreement with Alteogen to develop a subcutaneous formulation of dostarlimab — a commercial/technical collaboration of modest, longer?term impact. Alteogen Announces Exclusive License Agreement…
• Neutral Sentiment: GSK announced community grants (Linked by Lupus) and features in analyst comparisons (e.g., BMY vs GSK) — PR and coverage that have limited direct near?term valuation impact. GSK Announces Recipients of Linked by Lupus…
• Negative Sentiment: A shareholder law firm (Kahn Swick & Foti) is investigating whether the $58/share consideration and the sale process for RAPT were fair — this could lead to litigation or delayed integration and represents downside risk to sentiment. RAPT Therapeutics Investor Alert…

GSK Stock Up 0.9%

NYSE:GSK opened at $48.08 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.55 and a debt-to-equity ratio of 0.95. The stock has a 50 day moving average of $48.58 and a 200-day moving average of $43.69. The firm has a market capitalization of $98.01 billion, a PE ratio of 13.58, a price-to-earnings-growth ratio of 1.40 and a beta of 0.45. GSK has a 52 week low of $32.38 and a 52 week high of $51.46.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.22. The business had revenue of $11.35 billion during the quarter, compared to analyst estimates of $8.21 billion. GSK had a return on equity of 48.64% and a net margin of 17.16%.The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.50 EPS. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. Analysts predict that GSK will post 4.14 EPS for the current year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, January 8th. Shareholders of record on Friday, November 14th were paid a dividend of $0.4171 per share. The ex-dividend date of this dividend was Friday, November 14th. This represents a $1.67 annualized dividend and a yield of 3.5%. GSK’s payout ratio is presently 48.02%.

Insider Transactions at GSK

In other GSK news, major shareholder Plc Gsk purchased 1,470,000 shares of the firm’s stock in a transaction dated Thursday, December 11th. The stock was bought at an average price of $19.00 per share, with a total value of $27,930,000.00. Following the completion of the purchase, the insider owned 18,245,691 shares in the company, valued at $346,668,129. This trade represents a 8.76% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 10.00% of the company’s stock.

Institutional Investors Weigh In On GSK

A number of hedge funds and other institutional investors have recently modified their holdings of GSK. Fisher Asset Management LLC grew its position in GSK by 2.8% in the 3rd quarter. Fisher Asset Management LLC now owns 32,227,615 shares of the pharmaceutical company’s stock valued at $1,390,944,000 after buying an additional 889,210 shares in the last quarter. Miller Howard Investments Inc. NY lifted its stake in shares of GSK by 0.8% in the 2nd quarter. Miller Howard Investments Inc. NY now owns 1,659,814 shares of the pharmaceutical company’s stock worth $63,737,000 after acquiring an additional 13,023 shares during the period. Sound Income Strategies LLC boosted its holdings in shares of GSK by 7.3% in the second quarter. Sound Income Strategies LLC now owns 431,256 shares of the pharmaceutical company’s stock valued at $16,560,000 after acquiring an additional 29,197 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of GSK by 1.2% during the second quarter. Ameriprise Financial Inc. now owns 401,777 shares of the pharmaceutical company’s stock valued at $15,444,000 after acquiring an additional 4,855 shares during the period. Finally, Cullen Frost Bankers Inc. increased its stake in shares of GSK by 4.7% during the second quarter. Cullen Frost Bankers Inc. now owns 375,481 shares of the pharmaceutical company’s stock valued at $14,418,000 after acquiring an additional 16,999 shares during the period. 15.74% of the stock is currently owned by institutional investors.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.